🧬 Health & Longevity
AlphaGenome Atlas: predictions are not diagnoses
Announced on 8 September 2026, AlphaGenome Atlas contains precomputed molecular-effect predictions for roughly nine billion single-letter substitutions in…
🧬 All articles in
Health & Longevity
Medical robotics, AI-designed drugs, brain interfaces and the evidence behind longevity research.
🧬 Health & Longevity
Codex and antimicrobial research: candidates are not medicines
A 10 September 2026 OpenAI account describes César de la Fuente’s laboratory exploring genomic data for antimicrobial candidates. The team uses its own…
🧬 Health & Longevity
SynthID Bio: tracing AI-designed proteins
On 30 September 2026, Google DeepMind presented SynthID Bio, a proof of concept for identifying AI-designed proteins. The authors describe sequence and…
🧬 Health & Longevity
One cancer in eight may be preventable: what the global Lancet Oncology study found
A study in The Lancet Oncology estimates that about 12% of new cancer cases worldwide, or 2.3 million in 2024, are linked to infections. The primary article could not be opened.
🧬 Health & Longevity
Claude and DNA: what Anthropic’s biology lab actually found
Anthropic reports an ART enzyme system associated with DNA repeats. The technical report, human lab work and the limits of the medical interpretation.
🧬 Health & Longevity
Robot knee surgery: what a 68-patient trial proves
A randomized human trial of ROSA-assisted knee replacement found better alignment and some early benefits at three months, but it was small, single-centre and nine minutes longer.
🧬 Health & Longevity
AI stethoscope in pets: strong in dogs, poor in cats
A prospective study of 105 pets found that a human-trained digital stethoscope detected most dog murmurs but missed 20 of 22 cat murmurs and produced many false arrhythmia alerts.
🧬 Health & Longevity
Vicarious Surgical Is Liquidating Before Reaching the OR
Vicarious Surgical transferred its assets for liquidation before FDA authorization or sales. The filing shows why medical robots need long runways.
🧬 Health & Longevity
An AI-Discovered Drug Reached Phase 2: What Rentosertib Proved — and Didn't
Rentosertib produced an encouraging signal in a small pulmonary-fibrosis trial. It also shows why AI cannot skip clinical evidence.
🧬 Health & Longevity
Autonomous Surgery in 2026: What Robots Can Really Do Without a Surgeon
A research robot completed a complex procedure on realistic tissue models. Today's cleared surgical systems remain under direct physician control.
🧬 Health & Longevity
Can Big Tech Slow Aging? What Alphabet's Calico Is Actually Building
Alphabet-backed Calico studies the biology of aging, but its public clinical pipeline is about specific diseases—not immortality.
🧬 Health & Longevity
Brain Implants in 2026: Neuralink, Synchron and the Reality Behind the Demos
Early feasibility studies are testing whether people with severe paralysis can control digital devices. That is not mind reading or human enhancement.
🧬 Health & Longevity
New Cancer Medicines in 2026: Targeted Advances, Not a Universal Cure
Recent U.S. approvals show how cancer treatment is becoming more precise: a defined tumour, biomarker and treatment history—not one medicine for every cancer.
🧬 Health & Longevity
The First Cellular-Rejuvenation Trial Has Begun: What ER-100 Is Really Testing
ER-100 is testing partial epigenetic reprogramming in up to 18 people with optic-nerve disease. It is a local phase 1 safety study, not whole-body rejuvenation.
🧬 Health & Longevity
CRISPR Therapies in 2026: What Is Approved and What Remains Experimental
CRISPR has produced an authorised treatment for blood disorders, but the procedure remains demanding and gene editing is not yet a universal cure.
🧬 Health & Longevity
Hair-Regrowth Drugs 2026: PP405, Clascoterone, Evidence
PP405 targets dormant follicles and clascoterone local androgen signalling. Both remain investigational despite encouraging company releases.
🧬 Health & Longevity
Neuralink's Robot-Arm Trial: What CONVOY Is Actually Testing
Neuralink's CONVOY tests brain-implant control of an assistive robot arm in three participants. It is an early feasibility study, not restored movement.
🧬 Health & Longevity
Obesity Drugs in 2026: The New GLP-1 Pill, Retatrutide and the Safety Gap
Orforglipron is now approved in the United States, while retatrutide remains investigational. The gap matters as unapproved versions spread online.
🧬 Health & Longevity
Senolytics in 2026: What Human Trials Actually Show
Drugs that clear senescent cells are being tested in people, but today's studies are small and do not prove longer life.
🧬 Health & Longevity
TRG035 Tooth-Regrowth Drug: Where Toregem's Trials Really Stand in 2026
Where Toregem's TRG035 tooth-regrowth antibody really stands in 2026: real animal evidence, conflicting official trial-status pages — and no approved drug yet.
🧬 Health & Longevity
Pig Kidneys Transplanted into Humans: Where Xenotransplantation Stands in 2026
Genetically modified pig kidneys have functioned in living recipients, but rejection, infection and duration remain central questions for trials.